Estrogen Receptor-negative Breast Cancer Completed Phase 1 Trials for Veliparib (DB07232)

IndicationStatusPhase
DBCOND0028543 (Estrogen Receptor-negative Breast Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01104259Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast CancerTreatment